A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Arntz, Onno J ^a   Geurts, Jeroen ^a   Veenbergen, Sharon ^a   Bennink, Miranda B ^a   Van den Brand, Ben T ^a   Abdollahi Roodsaz, Shahla ^a   Van den Berg, Wim B ^a   Van de Loo, Fons A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RECEPTOR 1; TNFRSF1A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; LIVER; LYMPH NODE; MALE; MOUSE; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; SPLEEN; SYNOVIOCYTE; TH1 CELL; ADENOVIRUS; ANIMAL; C57BL MOUSE; DBA MOUSE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MONONUCLEAR PHAGOCYTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM;

ADENOVIRIDAE; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MONONUCLEAR PHAGOCYTE SYSTEM; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; SPLEEN; SYNOVIAL MEMBRANE;

EID: 77950535846     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2974     Document Type: Article

References (57)

1. Joosten LA, Helsen MM, Loo FA, Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809. 10.1002/art.1780390513, 8639177.
2. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89:9784-9788. 10.1073/pnas.89.20.9784, 50217, 1409699.
3. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031. 453150, 1721867.
4. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2:244-247. 10.1016/S0140-6736(89)90430-3, 2569055.
5. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993, 36:1681-1690. 10.1002/art.1780361206, 8250987.
6. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344:1125-1127. 10.1016/S0140-6736(94)90632-7, 7934495.
7. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002, 14:477-492. 10.1016/S0898-6568(01)00262-5, 11897488.
8. Mori L, Iselin S, De LG, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 1996, 157:3178-3182.
9. Tada Y, Ho A, Koarada S, Morito F, Ushiyama O, Suzuki N, Kikuchi Y, Ohta A, Mak TW, Nagasawa K. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1. Clin Immunol 2001, 99:325-333. 10.1006/clim.2001.5027, 11358427.
10. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008, 205:331-337. 10.1084/jem.20070906, 2271010, 18250193.
11. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008, 205:2491-2497. 10.1084/jem.20072707, 2571924, 18936235.
12. Williams-Skipp C, Raman T, Valuck RJ, Watkins H, Palmer BE, Scheinman RI. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum 2009, 60:408-418. 10.1002/art.24260, 2650479, 19180511.
13. Barrera P, Oyen WJ, Boerman OC, van Riel PL. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:825-828. 10.1136/ard.62.9.825, 1754647, 12922953.
14. Broek MF, Berg WB, Putte LB, Severijnen AJ. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988, 133:139-149. 1880648, 3052092.
15. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998, 95:2509-2514. 10.1073/pnas.95.5.2509, 19394, 9482916.
16. Schiedner G, Hertel S, Kochanek S. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 2000, 11:2105-2116. 10.1089/104303400750001417, 11044912.
17. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004, 78:5368-5381. 10.1128/JVI.78.10.5368-5381.2004, 400378, 15113916.
18. Veenbergen S, Bennink MB, de Hooge AS, Arntz OJ, Smeets RL, Berg WB, Loo FA. Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses and prevents development of collagen-induced arthritis. Arthritis Rheum 2008, 58:3742-3752. 10.1002/art.24072, 19035473.
19. Wu L, Belasco JG. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 2008, 29:1-7. 10.1016/j.molcel.2007.12.010, 18206964.
20. Berg WB, Joosten LA, Kollias G, Loo FA. Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis 1999, 58(Suppl 1):I40-I48. 10.1136/ard.58.2008.i40, 1766568, 10577972.
21. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, Dinarello CA, Paul WE. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009, 106:7119-7124. 10.1073/pnas.0902745106, 2678417, 19359475.
22. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204:41-47. 10.1084/jem.20062259, 2118414, 17227914.
23. Cowley SC, Sedgwick JD, Elkins KL. Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth. J Immunol 2007, 179:7709-7719.
24. Muller S, Rihs S, Schneider JM, Paredes BE, Seibold I, Brunner T, Mueller C. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death. Eur J Immunol 2009, 39:3171-3180. 10.1002/eji.200939554, 19681056.
25. Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, Kollias G, Aidinis V. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One 2006, 1:e108. 10.1371/journal.pone.0000108, 1762410, 17205112.
26. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007, 179:1872-1883.
27. Butler DM, Feldmann M, Di PF, Brennan FM. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw 1994, 5:441-448.
28. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med 1998, 188:1343-1352. 10.1084/jem.188.7.1343, 2212501, 9763613.
29. Yamaguchi N, Ohshima S, Umeshita-Sasai M, Nishioka K, Kobayashi H, Mima T, Kishimoto T, Saeki Y. Synergistic effect on the attenuation of collagen induced arthritis in tumor necrosis factor receptor I (TNFRI) and interleukin 6 double knockout mice. J Rheumatol 2003, 30:22-27.
30. Ermolaeva MA, Michallet MC, Papadopoulou N, Utermohlen O, Kranidioti K, Kollias G, Tschopp J, Pasparakis M. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol 2008, 9:1037-1046. 10.1038/ni.1638, 18641654.
31. Zakharova M, Ziegler HK. Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J Immunol 2005, 175:5024-5033.
32. Gouze E, Gouze JN, Palmer GD, Pilapil C, Evans CH, Ghivizzani SC. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther 2007, 15:1114-1120.
33. Smith JS, Xu Z, Tian J, Stevenson SC, Byrnes AP. Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum Gene Ther 2008, 19:547-554. 10.1089/hum.2008.004, 18447633.
34. Hiltunen MO, Turunen MP, Turunen AM, Rissanen TT, Laitinen M, Kosma VM, Yla-Herttuala S. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. FASEB J 2000, 14:2230-2236. 10.1096/fj.00-0145com, 11053244.
35. Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni S, Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol 2007, 81:4866-4871. 10.1128/JVI.02819-06, 1900148, 17301138.
36. van Lent PL, Holthuysen AE, Bersselaar LA, van RN, Joosten LA, Loo FA, Putte LB, Berg WB. Phagocytic lining cells determine local expression of inflammation in type II collagen-induced arthritis. Arthritis Rheum 1996, 39:1545-1555. 10.1002/art.1780390915, 8814067.
37. Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999, 38:818-825. 10.1093/rheumatology/38.9.818, 10515641.
38. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, Bersselaar LA, Koenders MI, Berg WB. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum 2008, 58:3753-3764. 10.1002/art.24127, 19035506.
39. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, Akira S, Lubberts E, Loo FA, Berg WB. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003, 171:6145-6153.
40. Alsalameh S, Amin RJ, Kunisch E, Jasin HE, Kinne RW. Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55. J Rheumatol 2003, 30:1680-1690.
41. Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R, Kinne RW. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1043-1051. 10.1136/ard.2006.062521, 17223661.
42. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den BW, Schett G. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007, 104:11742-11747. 10.1073/pnas.0610812104, 1913858, 17609389.
43. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, Loo FA, Berg WB. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997, 40:893-900. 10.1002/art.1780400517, 9153551.
44. Lubberts E, Joosten LA, van den BL, Helsen MM, Bakker AC, Xing Z, Richards CD, Berg WB. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin Exp Immunol 2000, 120:375-383. 10.1046/j.1365-2249.2000.01217.x, 1905648, 10792391.
45. Mukherjee P, Wu B, Mayton L, Kim SH, Robbins PD, Wooley PH. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis 2003, 62:707-714. 10.1136/ard.62.8.707, 1754640, 12860724.
46. Mukherjee P, Yang SY, Wu B, Song Z, Myers LK, Robbins PD, Wooley PH. Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice. Ann Rheum Dis 2005, 64:1550-1556. 10.1136/ard.2004.025619, 1755256, 15860512.
47. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, Robbins PD, Evans CH. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999, 162:3625-3632.
48. Whalen JD, Thomson AW, Lu L, Robbins PD, Evans CH. Viral IL-10 gene transfer inhibits DTH responses to soluble antigens: evidence for involvement of genetically modified dendritic cells and macrophages. Mol Ther 2001, 4:543-550. 10.1006/mthe.2001.0492, 11735338.
49. Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002, 6:591-600. 10.1016/S1525-0016(02)90711-2, 12409257.
50. Eriksson U, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, Hunziker L, Suzuki S, Bachmaier K, Bingisser RM, Penninger JM, Kopf M. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med 2003, 197:323-331. 10.1084/jem.20021788, 2193833, 12566416.
51. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000, 1:510-514. 10.1038/82763, 11101873.
52. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220. 10.1084/jem.174.5.1209, 2119001, 1940799.
53. Boots AM, Wimmers-Bertens AJ, Rijnders AW. Antigen-presenting capacity of rheumatoid synovial fibroblasts. Immunology 1994, 82:268-274. 1414827, 7927499.
54. Tran CN, Davis MJ, Tesmer LA, Endres JL, Motyl CD, Smuda C, Somers EC, Chung KC, Urquhart AG, Lundy SK, Kovats S, Fox DA. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis Rheum 2007, 56:1497-1506. 10.1002/art.22573, 17469112.
55. Zimmermann T, Kunisch E, Pfeiffer R, Hirth A, Stahl HD, Sack U, Laube A, Liesaus E, Roth A, Palombo-Kinne E, Emmrich F, Kinne RW. Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. Arthritis Res 2001, 3:72-76. 10.1186/ar142, 17827, 11178129.
56. Tran CN, Lundy SK, White PT, Endres JL, Motyl CD, Gupta R, Wilke CM, Shelden EA, Chung KC, Urquhart AG, Fox DA. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 2007, 171:1588-1598. 10.2353/ajpath.2007.070004, 2043519, 17823284.
57. Wang M, Markel T, Crisostomo P, Herring C, Meldrum KK, Lillemoe KD, Meldrum DR. Deficiency of TNFR1 protects myocardium through SOCS3 and IL-6 but not p38 MAPK or IL-1beta. Am J Physiol Heart Circ Physiol 2007, 292:H1694-H1699. 10.1152/ajpheart.01063.2006, 17114246.